Establishment Labs Holdings Inc. (NASDAQ:ESTA) Holdings Trimmed by Magnetar Financial LLC

Magnetar Financial LLC lowered its stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 14.5% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 46,622 shares of the company’s stock after selling 7,892 shares during the period. Magnetar Financial LLC owned approximately 0.17% of Establishment Labs worth $2,119,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Hood River Capital Management LLC acquired a new stake in shares of Establishment Labs during the second quarter valued at approximately $43,000. Nkcfo LLC purchased a new stake in shares of Establishment Labs during the 2nd quarter worth about $227,000. Sei Investments Co. lifted its holdings in shares of Establishment Labs by 634.5% during the 2nd quarter. Sei Investments Co. now owns 40,576 shares of the company’s stock valued at $1,844,000 after buying an additional 35,052 shares during the last quarter. Divisadero Street Capital Management LP bought a new position in shares of Establishment Labs during the 2nd quarter valued at $5,829,000. Finally, Sofinnova Investments Inc. lifted its position in shares of Establishment Labs by 204.1% in the second quarter. Sofinnova Investments Inc. now owns 429,244 shares of the company’s stock worth $19,505,000 after buying an additional 288,082 shares during the last quarter. Hedge funds and other institutional investors own 72.91% of the company’s stock.

Insider Buying and Selling at Establishment Labs

In other Establishment Labs news, CEO Quiros Juan Jose Chacon sold 3,641 shares of Establishment Labs stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $45.04, for a total value of $163,990.64. Following the sale, the chief executive officer now directly owns 210,735 shares in the company, valued at approximately $9,491,504.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last quarter, insiders have sold 14,346 shares of company stock worth $647,806. Corporate insiders own 11.44% of the company’s stock.

Establishment Labs Trading Down 5.5 %

ESTA opened at $40.13 on Tuesday. Establishment Labs Holdings Inc. has a fifty-two week low of $16.96 and a fifty-two week high of $60.12. The company has a market cap of $1.10 billion, a price-to-earnings ratio of -12.78 and a beta of 1.20. The company has a debt-to-equity ratio of 4.30, a current ratio of 4.44 and a quick ratio of 2.91. The firm has a 50 day simple moving average of $43.51 and a 200 day simple moving average of $47.53.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.11). The company had revenue of $44.12 million during the quarter, compared to analyst estimates of $43.10 million. Establishment Labs had a negative net margin of 54.97% and a negative return on equity of 220.67%. The business’s revenue for the quarter was down 9.2% compared to the same quarter last year. During the same period last year, the company earned ($0.65) EPS. On average, sell-side analysts anticipate that Establishment Labs Holdings Inc. will post -2.2 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have commented on ESTA shares. Citigroup increased their price target on Establishment Labs from $41.00 to $45.00 and gave the company a “neutral” rating in a report on Thursday, August 22nd. Mizuho boosted their price target on shares of Establishment Labs from $65.00 to $70.00 and gave the company a “buy” rating in a report on Thursday, June 6th. Stephens reiterated an “overweight” rating and set a $68.00 target price on shares of Establishment Labs in a research report on Wednesday, August 7th. Finally, JPMorgan Chase & Co. lowered their price target on Establishment Labs from $61.00 to $50.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 7th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $56.60.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.